- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
BMS, Kereos collaborate on imaging agents
Bristol-Myers Squibb Medical Imaging and Kereos have agreed to partner in the development and commercialization of novel molecular imaging agents. The goal is to develop agents that will detect disease on a molecular level, potentially enabling earlier
Bristol-Myers Squibb Medical Imaging and Kereos have agreed to partner in the development and commercialization of novel molecular imaging agents. The goal is to develop agents that will detect disease on a molecular level, potentially enabling earlier and more effective diagnosis and highly targeted treatment of cardiovascular diseases and cancer. The companies will work together to develop molecular imaging agents using Kereos' core technology. BMS Medical Imaging has obtained exclusive worldwide rights to develop and commercialize select cardiovascular molecular imaging agents for MR. Kereos has obtained exclusive worldwide rights to use a family of BMS targeting molecules with Kereos' core technology to develop and commercialize imaging agents and targeted therapeutics. These include KI-001, Kereos' lead candidate for early MR detection of tumors. In addition to working with BMS, Kereos is collaborating with Philips Medical Systems for the development of molecular imaging systems.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
